SK Biopharmaceuticals Co Ltd
326030
Company Profile
Business description
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.
Contact
221, Pangyoyeok-ro
Bundang-gu
Gyeonggi-do
Seongnam-si13494
KORT: +82 3180930114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
265
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,017.50 | 50.80 | 0.57% |
| CAC 40 | 7,857.36 | 56.48 | 0.72% |
| DAX 40 | 24,217.37 | 247.01 | 1.03% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,136.32 | 54.88 | 0.60% |
| HKSE | 25,416.42 | 108.03 | -0.42% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,657.48 | 17.07 | -0.04% |
| NZX 50 Index | 12,963.50 | 27.09 | 0.21% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,758.60 | 54.00 | 0.62% |
| SSE Composite Index | 3,626.12 | 16.41 | 0.45% |